glp 1 conference Yet another large database study is tying GLP-1 drugs to potential benefits in cancer, suggesting that some patients prescribed the medications after cancer diagnosis have a significantly decreased rate of progression to Moving Beyond GLP-1: The Next

Sepahi M

Injectable dose: 1-2mg daily subcutaneous Optional topical: 0.5-2% solution to problem areas Timing: Any time of day, food intake does not affect absorption Cycle length: 8-12 weeks on, 4-6 weeks off When to start: After 15-20lb weight loss or preemptively TB-500: Systemic Recovery and Inflammation Thymosin Beta-4 fragment, commonly known as TB-500, provides whole-body recovery support through mechanisms distinct from other healing peptides

Consider continuation or tapering strategy 4

weight loss ~21% over 72 wks Dual GIP / GLP-1 Included *Average weight-loss figures reference published clinical trials (STEP for semaglutide, SURMOUNT for tirzepatide)